Andrew Mearns Spragg,
Jellagen Pty Ltd, UK
Title: Jellyfish collagen biomaterials - Next generation collagen for cell culture and med-tech products
Biography
Biography: Andrew Mearns Spragg,
Abstract
Jellagen Pty Ltd (JPL) founded in August 2013, is a Med-Tech business exploiting jellyfish to provide the next generation of collagen biomaterials that are safer and more technically versatile than current sources of mammalian derived collagen products for application in 3D cell culture (in vitro diagnostics, including research level regenerative medicine R&D) and medical devices. JPL’s research grade materials are on market and our vision is to be the leading provider of medical grade nonmammalian collagen products to these markets in addition to conducting in-house development of new medical devices for wound and cartilage repair. Jellagen offers the following next generation collagen products for research application: Research grade acid and enzyme soluble and powdered native collagen; Collagen sponge scaffolds for 3D cell culture; Hydrogels (3D cell culture and tissue engineering application) and; Prototype bio-mimetic collagen membrane medical device products (at pre-clinical stage).
